Odense, Denmark, September 10, 2018 / B3C newswire / — RSP Systems A/S, the non-invasive diagnostics company, announces that it has completed second closing of its Series B round. This closing brings in an additional EUR 3,85 million making the round EUR 10,35 million in total. The proceeds will be used to fund clinical trials and to prepare for regulatory approval and market launch in Europe.

Existing, as well as new investors, have contributed to RSP Systems’ Series B round. Among these new investors is TRUMPF Venture, the corporate venture arm of the TRUMPF Group – the market and technology leader in machine tools and lasers.

RSP System’s CEO, Andreas Jenne, said, “We are grateful for the loyal support of existing shareholders and are excited to have attracted new and equally savvy shareholders in this second closing. The participation of TRUMPF Venture points to the fact that we are on track towards sourcing, production, and commercialization; the timing of this could not have been better.”

Dr. Dieter Kraft, managing director of TRUMPF Venture GmbH pointed out, “We are very happy to be part of the RSP support team. RSP Systems is expected to be the breakthrough innovator the medical industry has waited decades for. For TRUMPF the investment allows insights to new application areas of photonic systems where we can bring additional value based on our knowledge.”